Allogeneic stromal cells for canine osteoarthritis
Description/summary
The goal of this study is to evaluate the ability of a specific stem cell product (Jango-Renew) to alleviate symptoms associated with arthritis in dogs. Jango-Renew is a proprietary allogeneic stromal cell treatment, which means that it contains stem cells (i.e. cells that have the potential to develop into different types of cells in the body and communicate with other cells) collected from another (donor) dog.
The procedure of using cells from a donor dog (“allogeneic” cells) has been utilized in several other research studies (including research performed here at CSU using cells produced at CSU). However, this is the first study at CSU using Jango-Renew cells.
A possible downside of using cells from another dog is the transmission of disease, meaning infectious diseases present in the donor dog could be transmitted to your dog. To mitigate this risk, the producer screens potential donors for over 30 common canine pathogens (donors must test negative), ensures donors are current on mandatory vaccines, and ensures that doses are sterile (do not contain bacterial contamination) and free from genetic material of other pathogens (mycoplasma). The benefit of using cells from another dog is that your dog does not have to undergo a procedure to collect the cells. Jango-Renew is produced by JangoPet. The manufacturer performed initial safety testing on Jango-Renew in 12 dogs and has not reported any adverse events in any of the dogs. In addition, all 12 dogs showed improvement post-injection as measured by owner survey and canine mobility testing (described below), as compared to pre-injection scores, and to varying degrees and for varying durations.
Owner commitments
- Adhere to a strict timeline for study schedule.
- Have the ability to complete multiple required digital questionnaires via email at specified time points
- Have the ability to complete multiple required digital questionnaires in person at specified time points
- Be willing to stay in hospital for about two hours to participate in mobility testing.
- Have the ability to respond to email requests and phone calls within two business days
Enrollment benefits
- Initial evaluation
- X-rays, CT, and/or MRI
- Bloodwork
- Treatment with Jango-Renew – stem cell therapy will be administered to one or more joints of your dog (depending on your dog’s needs)
condition(s)
eligibility information
- Older than 1 year of age
- Weight between 10kg-45.5kg
- Spayed/neutered
- No brachycephalic breeds will be enrolled
- Radiographic evidence of arthritis present in the hips, shoulder, elbows, or knees
- Acclimated to a collar and able to wear one 24/7
- Overall friendly demeanor and able to participate in blood draws, examinations, and general handling
*Please note that the enrollment inclusion/exclusion criteria extend beyond this list. Be prepared to complete multiple questionnaires and provide a minimum of 1.5 years of records for your pet.
Enrollment Deadline
Enrollment ends November 1, 2026
contact information
If you are interested in enrolling in this clinical trial, please email Clinical Trials Coordinator Beth Romero at [email protected] for next steps.